2024 SEAAIS 79th Annual Meeting

Asheville, NC US
September 19, 2024 to September 22, 2024

The SEAAIS conference is focused on the field of Allergy, Asthma and Immunology.  It is directed to physicians, physician assistants, nurse practitioners and administrators.  The purpose is to engage the audience through oral didactic presentations followed by group discussions.  Each presentation is reflective of a need or interest of in-depth conversation or study requested by the membership and/or board.  Case presentations are often utilized to solidify the objectives covered in each presentation.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunology and Southeastern Allergy, Asthma & Immunology Society, Inc (SEAAIS). The American College of Allergy, Asthma & Immunology is accredited by the ACCME to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 12.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 12.5 contact hours.

Commercial Support
This activity is supported in part by independent medical education grants from Pharming and Takeda.

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

At the conclusion of this activity learners should be able to…

1.  Demonstrate that IgE targeting therapies can be effective in CRSwNPs but not because it is an allergic disease, assess how IL-5 targeting therapies can be effective in CRSwNPs but not necessarily because they target eosinophils and learn the rofe for IgG4 in CRSwNPs.
2.  Examine the role of bystander allergic reactions in the pathogenesis of RV-induced asthma exacerbations and describe the role of aberrant innate immune responses in RV-associated asthma exacerbations.
3. Recognize and adapt to changes for the practicing allergist/immunologist, prepare alternate income sources and identify tax advantaged investments.
4. Examine the treatment applications for the patient with nasal polyps from an ENT’s perspective and evaluate clinical criteria for a surgical approach to treatment for nasal polyps.
5. Develop an understanding of laboratory assessment of inborn errors of immunity, evaluate genetic testing for IEI, and plan how to incorporate resources into evaluation and diagnosis of IEI.
6. Develop an understanding of immune dysregulation and how it might present in the allergy office and learn updated pneumococcal vaccines and their use in immunodeficiency evaluation.
7.  Examine causes of hoarseness in the allergy/immunology patients, discuss treatment options and when to refer to an ENT.
8.  Understand the evolution of AI in Healthcare, identify opportunities and challenges, and explore ethical considerations in AI integration.
9.  Illustrate how to interpret serum tryptase measurements and prepare participants to treat anaphylaxis and systemic allergic reactions.
10.  Demonstrate current literature being reviewed for current practice parameter in development, and recommend participants how to utilize most effective allergen immunotherapy.
11.  Describe variations in practice for venom allergy testing, use joint decision making in selecting venom extracts and review the risks and benefits of spacing/discontinuing venom immunotherapy.
12.  Describe the different types of inflammation caused by arthropod bites, stings and infestations, and demonstrate characteristics of immune responses to identify likely culprits for cryptic arthropod bite reactions.
13.  Learn key updates in CIU and novel therapies on the horizon to improve patient outcomes.
14.  Evaluate a multi-disciplinary approach to manage the chronic cough patient and gain knowledge of effective treatment plans.
15.  Learn recent topic updates in the US Drug Allergy Practice Parameters and discuss key updates on penicillin, cephalosporin and sulfonamide testing.
16.  Evaluate the costs and benefits of MOC for allergists, review the continuous assessment program and discuss the role of the ABAI for the practicing allergist.
17.  Analyze multiple conditions of the airway associated with GE reflux and understand two potential mechanisms that help explain how airway disease might predispose to GE reflux.

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 12.50 AMA PRA Category 1 Credit™
  • 12.50 Attendance
  • 12.50 CBRN
Course opens: 
09/19/2024
Course expires: 
12/31/2025
Event starts: 
09/19/2024 - 6:45pm CDT
Event ends: 
09/22/2024 - 11:00am CDT
Rating: 
0

Thursday, September 19 - NON-CME
6:45 - 7:30 PM Dinner

Friday, September 20

7:30 – 8:00 AM BREAKFAST IN EXHIBITOR HALL – Heritage B & C    
8:00 – 8:05 AM Welcome and Opening Remarks, Lee S. Clore, Jr., MD, Executive Secretary-Treasurer
8:05 – 8:45 AM Novel Insights into the Pathogenesis of Eosinophilic Nasal Polyps and Implications for Treatment, Larry Borish, MD
8:45 – 9:25 AM The Allergist in Transition, Jack Eades, MD
9:25 – 10:05 AM Nasal Polyps: Why Surgery is Important, Thomas Higgins, MD
10:05 – 10:15 AM Question & Answer Session, Lee S. Clore, Jr., MD
10:15 – 10:45 AM BREAK IN EXHIBITOR HALL - Heritage B & C    
10:45 – 11:25 AM Immunodeficiency Evaluation in 2024: Overview and Clinical Applications, Niraj Patel, MD
11:25 AM – 12:10 PM Hoarseness – Causes, Treatment and When to Refer to an ENT, Elizabeth Burckardt, MD
12:10 – 12:55 PM LUNCH IN EXHIBITOR HALL - Heritage B & C    
1:00 – 1:40 PM Augmented Intelligence in Healthcare: Practice Management Symposium: brought to you by the American College of Allergy, Asthma & Immunology, Jay Portnoy, MD
1:40 – 2:20 PM Anaphylaxis Versus Systemic Reactions: Does it Matter?, Dennis Ledford, MD
2:20 – 2:30 PM Question & Answer Session, Lee S. Clore, Jr., MD
2:30 – 3:00 PM    BUSINESS MEETING – Members Only Please Lee S. Clore, Jr., MD *NON-CME*
 
Saturday, September 21

7:30 – 8:00 AM BREAKFAST IN EXHIBITOR HALL – Heritage B & C    
8:00 – 8:05 AM Welcome & Opening Remarks, Joseph Turbyville, MD President-Elect
8:05 – 8:45 AM Inhalant Allergen Immunotherapy: Anything New?, Dennis Ledford, MD
8:45 – 9:25 AM Controversies in Venom Allergy Diagnosis and Management, John Carlson, MD
9:25 – 10:05 AM Airway Epithelial Cell Dysfunction: Implications for Rhinovirus-Induced Asthma Exacerbations, Larry Borish, MD
10:05 – 10:15 AM Question & Answer, Joseph Turbyville, MD
10:15 – 10:45 AM BREAK IN EXHIBITOR HALL - Heritage B & C    
10:45 – 11:25 AM CIU Update, David Khan, MD
11:25 AM – 12:25 PM Poster Symposium, Joseph Turbyville, MD *NON-CME*
12:25 – 1:05 PM LUNCH IN EXHIBITOR HALL - Heritage B & C    
1:10 – 1:50 PM Hot Topics in Immunology: What the Allergist Needs to Know, Niraj Patel, MD, John A. Yarbrough, MD Memorial Lecture
1:50 – 2:30 PM Snot Wars: Chronic Cough and Vocal Cord Dysfunction Panel, Thomas Higgins, MD; Larry Borish, MD; Elizabeth Burckhardt, MD;
2:30 – 2:40 PM Question and Answer Session, Joseph Turbyville, MD
 
Sunday, September 22 

8:15 – 8:20 AM Welcome & Opening Remarks, Scott Commins, MD, PhD
8:20 – 9:00 AM Antibiotic Allergy, David Khan, MD
9:00 – 9:40 AM ABAI Update, David Amrol, MD
9:40 – 10:20 AM Evaluation of Anthropod Bites, Stings and Infestations, John Carlson, MD
10:20 – 11:00 AM One Airway and the Esophagus: Is GE Reflux the Chicken or the Egg?, Joseph Turbyville, MD
11:00 – 11:10 AM Questions & Closing Remarks, Scott Commins, MD, PhD

Omni Grove Park Inn
290 Macon Avenue
Asheville, NC 28804
United States

All relevant financial relationships with ineligible companies have been mitigated.
 
David Amrol, MD, Speaker
Speaker - AstraZeneca, Incyte

Larry Borish, MD, Speaker
Consultant – Advocate, DevPro, AstraZeneca, GSK, Sanofi, Regeneron; Researcher – Advocate, Regeneron

John Carlson, MD, Speaker
Researcher – AstraZeneca

Lee S. Clore, Jr., MD, Moderator
Advisor – Incyte; Speaker – Sanofi, Regeneron, GSK, Pharming, AstraZeneca; Researcher – Sanofi, Regeneron, GSK, AstraZeneca, Novartis, Escient Pharmaceuticals, OM Pharma, Eli Lilly

Scott Commins, MD, PhD, Moderator
Speaker – Genentech; Researcher – Revivicor

Jack R. Eades, MD, Speaker
Speaker – Carwin, Pharming

Thomas Higgins, MD, MSPH, EMBA, Speaker
Speaker – Optinose, Sanofi, Regeneron, Medtronic; Consultant – Stryker; Researcher – Biohave (Pfizer), Spirair, Cryano

Dennis Ledford, MD, Speaker
Speaker – AstraZeneca, GSK, Sanofi Regeneron; Consultant – AstraZeneca; Researcher – AstraZeneca

Niraj Patel, MD, Speaker
Speaker – Takeda, Amgen, Pharming; Advisor – CSL Behring; Researcher – Takeda, CSL Behring; Consultant – Takeda, DSMB - Janssen

Jay Portnoy, MD, Speaker
Speaker - ThermoFischer

The following have no relevant financial relationships with ineligible companies to disclose:

Elizabeth Burckardt, MD, Speaker
J. Trent Ellenburg, DO, Planner
David Khan, MD, Speaker
Jean Owen, MBA, Planner
Joseph Turbyville, MD, Planner/Moderator

Available Credit

  • 12.50 AMA PRA Category 1 Credit™
  • 12.50 Attendance
  • 12.50 CBRN
Please login or create an account to take this course.